Atreca is a biotechnology company developing novel therapeutics drawn from human immune responses, including effective anti-Âcancer immune responses. We are able to measure and analyze the structure of clinically relevant immune responses to identify the antibodies, T cell receptors, and targets that are key to successful treatment outcomes. Atrecaâs proprietary Immune Repertoire CaptureÂŽ technology profiles a patientâs immune response at the single-Âcell level at very high throughput essentially without bias or error, enabling the identification and generation of functional human antibodies and TCRs without prior knowledge of antigen. The Company is advancing a pipeline of candidates designed to engage the human immune response in oncology and other indications, thus driving better therapeutic outcomes. Source
No articles found.
Robovet Corporation has developed a new MR imaging technology that can also help t...
Robovet Corporation has developed a new MR imag...
Ansell Limited provides health and safety protection solutions. The Company has op...
Ansell Limited provides health and safety prote...
Enochian Biosciences is a pre-clinical stage biotechnology company committed to us...
Enochian Biosciences is a pre-clinical stage bi...
ContraFect is a clinical-stage biotechnology company focused on discovering and de...
ContraFect is a clinical-stage biotechnology co...
Sonoma Pharmaceuticals is a specialty pharmaceutical company that develops and mar...
Sonoma Pharmaceuticals is a specialty pharmaceu...
Harrow Health, Inc. (NASDAQ: HROW) owns a portfolio of healthcare businesses, incl...
Harrow Health, Inc. (NASDAQ: HROW) owns a portf...
PDS Biotechnology has a growing pipeline of clinical-stage immunotherapies to trea...
PDS Biotechnology has a growing pipeline of cli...
Join the National Investor Network and get the latest information with your interests in mind.